Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
AstraZeneca Chief Executive Pascal Soriot, responding to rumors he might leave the drugmaker to join rival Teva Pharmaceutical Industries, has told staff he expects to work together with employees to see the company succeed. A company spokeswoman added he was intending to attend the European Society for Medical Oncology (ESMO) annual meeting in Madrid in September, assuming that AstraZeneca had clinical data on its new immunotherapy medicine ready to present at the event. Soriot did not comment on whether he had received a job offer from Teva in the internal memo to staff, which was sent out at the start of this week.
AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).
Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.
Англичане обвиняют в экоциде Monsanto, которая идет в «незалежную»
Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.
Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.
Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.
Uncertainty over the future of AstraZeneca (AZN.L) Chief Executive Pascal Soriot drove the Anglo-Swedish drugmaker's shares lower again on Friday, taking the cost of two days of silence to more than 3 billion pounds. AstraZeneca has repeatedly declined to comment on an Israeli media report on Wednesday that said the well-regarded Soriot was in talks to join Israel's Teva Pharmaceutical Industries (TEVA.TA), the world's biggest generic drugmaker. AstraZeneca shares closed 3.5 percent lower on Thursday and were down 2.5 percent on Friday at a two-month low after the company said it would not comment on rumours or speculation.
The London market lost ground on Friday, with Royal Mail and house builders seeing some of the biggest falls.
We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.
The City watchdog’s rewriting of the premium listing rules to accommodate a potential mega-listing in London of Aramco is deplorableNow we know how the City will be kept open for business after Brexit. If a foreign government, in this case Saudi Arabia’s royal family, doesn’t like the rules in London, the UK is happy to be flexible.For some, the Financial Conduct Authority’s proposed rewrite of the listing rules to woo state-backed companies is a fuss about nothing. Aramco is an enormous beast that will shower fees on bankers and lawyers, and maybe also burnish London’s standing. It could easily float here under a so-called “standard” listing if it wished. But, if the price of keeping it away from New York is a tweak to the definition of a prestige “premium” listing, so be it. Continue reading...
FTSE 100 edges lower as AstraZeneca loses steam